Azopax

Azopax Therapeutics was a biopharmaceutical company headquartered in Wellesley, Massachusetts, focused on the development of novel drug delivery systems. The company's core expertise lay in creating sustained-release formulations for therapeutic peptides and proteins, with a primary focus on exendin-4 for metabolic conditions. Its technology platform utilized biodegradable macromers and macromer-melt formulations to achieve controlled release of active biological substances. Azopax was active during the early 2000s before its intellectual property assets were assigned to Argonaut 26 LLC in 2006. The company's research aimed to address unmet needs in diabetes, obesity, and endocrine disorders through improved delivery kinetics.